Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) have received a consensus rating of “Moderate Buy” from the fourteen research firms that are presently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has issued a strong […]
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the fourteen research firms that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has given a strong buy […]
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price objective cut by Citigroup from $70.00 to $67.00 in a research note published on Friday, Benzinga reports. They currently have a buy rating on the stock. Other analysts have also recently issued reports about the company. Bank of America upgraded Apellis Pharmaceuticals from a neutral rating […]
Point72 Asset Management L.P. trimmed its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 34.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,239,361 shares of the company’s stock after selling 640,363 shares during the period. Point72 Asset Management […]